CONTENTS

Preface ix
Contributors xi
Introduction to Immunotoxicology xvii
Jack H. Dean

PART I CURRENT REGULATORY EXPECTATIONS FOR IMMUNOTOXICITY EVALUATION OF PHARMACEUTICALS 1

1 Current Regulatory Expectations for Immunotoxicity Evaluation of Pharmaceuticals 3
    Kenneth L. Hastings

PART II WEIGHT OF EVIDENCE REVIEW: A NEW STRATEGY IN IMMUNOTOXICOLOGY 11

2.1 Clinical Pathology as Crucial Insight into Immunotoxicity Testing 13
    Ellen Evans

2.2 Histomorphology of the Immune System: A Basic Step in Assessing Immunotoxicity 27
    Patrick Haley

2.3 Need for Specialized Immunotoxicity Tests 45
    Kazuichi Nakamura
2.4 Specific Drug-Induced Immunotoxicity: Immune-Mediated Hemolytic Anemia  
Raj Krishnaraj  

PART III NONCLINICAL CORE IMMUNOTOXICITY TESTING IN DRUG DEVELOPMENT  
3.1.1 T Cell-Dependent Antibody Response Tests  
Joseph R. Piccotti  
3.1.2 Natural Killer Cell Assay and Other Innate Immunity Tests  
Lisa Plitnick  
3.1.3 Cellular Immune Response in Delayed-Type Hypersensitivity Test  
Karen Price  
3.2 Evaluation of Drug Effects on Immune Cell Phenotypes  
Laurie Iciek  

PART IV EXTENDED IMMUNOTOXICOLOGY ASSESSMENT: EX VIVO MODELS  
4.1 Functional Cellular Responses and Cytokine Profiles  
Elizabeth R. Gore  
4.2 Application of Flow Cytometry in Drug Development  
Padma Narayanan, Renold J. Capocasale, Nianyu Li, and Peter J. Bugelski  

PART V EXTENDED IMMUNOTOXICOLOGY ASSESSMENT: IN VIVO MODELS  
5.1 Animal Models of Host Resistance  
Gary R. Burleson and Florence G. Burleson  
5.2 Approaches to Evaluation of Autoimmunity  
Danuta J. Herzyk  

PART VI IMMUNOTOXICITY TESTING IN BIOPHARMACEUTICAL DEVELOPMENT  
6.1 Differentiation between Desired Immunomodulation and Potential Immunotoxicity  
Jeanine L. Bussiere and Barbara Mounho
<table>
<thead>
<tr>
<th>Section</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.2 Relevant Immune Tests across Different Species and Surrogate Models</td>
<td>Jeanine L. Bussiere</td>
<td>199</td>
</tr>
<tr>
<td>6.3 Antidrug Antibody Responses in Nonclinical Studies and Their Implications</td>
<td>Barbara Mounho</td>
<td>209</td>
</tr>
<tr>
<td>7.1 Pharmacological Immunogenicity and Adverse Responses to Vaccines</td>
<td>Mary Kate Hart, Mark Bolanowski, and Robert V. House</td>
<td>219</td>
</tr>
<tr>
<td>7.2 Immunotoxicological Concerns for Vaccines and Adjuvants</td>
<td>Catherine Kaplanski, Jose Lebron, Jayanthi Wolf, and Brian Ledwith</td>
<td>229</td>
</tr>
<tr>
<td>8.1 Systemic Hypersensitivity</td>
<td>Raymond Pieters</td>
<td>241</td>
</tr>
<tr>
<td>8.2 Nonclinical Models to Assess Respiratory Hypersensitivity Potential</td>
<td>Curtis C. Maier</td>
<td>257</td>
</tr>
<tr>
<td>9.1 Developmental Immunotoxicity in Rodents</td>
<td>Rodney R. Dietert and Leigh Ann Burns-Naas</td>
<td>273</td>
</tr>
<tr>
<td>9.2 Developmental Immunotoxicity in Nonhuman Primates</td>
<td>Pauline L. Martin and Eberhard Buse</td>
<td>299</td>
</tr>
<tr>
<td>10.1 Alternative Animal Models for Immunomodulation and Immunotoxicity</td>
<td>Peter J. Bugelski</td>
<td>321</td>
</tr>
</tbody>
</table>